Polypeptide‑GalNAc‑T6 expression predicts better overall survival in patients with colon cancer
| Autor: | Edgardo Berriel, Sabina Victoria, Enrique Barrios, Nora Berois, Daniel Mazal, Luis Ubillos, Eduardo Osinaga |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Cancer Research Oncogene business.industry Colorectal cancer Mucin Cancer medicine.disease Molecular medicine Metastasis carbohydrates (lipids) 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Oncology 030220 oncology & carcinogenesis Cancer research Medicine Immunohistochemistry lipids (amino acids peptides and proteins) business Tumor marker |
| Zdroj: | Oncology Letters. |
| ISSN: | 1792-1082 1792-1074 |
| DOI: | 10.3892/ol.2018.8686 |
| Popis: | Colorectal carcinoma (CRC) is the second leading cause of cancer mortality worldwide. O-glycosylated mucins at the cell surface of colonic mucosa exhibit alterations in cancer and are involved in fundamental biological processes, including invasion and metastasis. Certain members of the GalNAc-transferase family may be responsible for these changes and are being investigated as novel biomarkers of cancer. In the present study the prognostic significance of GalNAc-T6 was investigated in patients with CRC patients. GalNAc-T6 expression was observed in all three colon cancer cell lines analyzed by reverse transcription-polymerase chain reaction, immunofluorescence and flow cytometry. A cohort of 81 colon cancer specimens was analyzed by immunohistochemical staining using MAb T6.3. It was demonstrated that GalNAc-T6 was expressed in 35/81 (43%) cases of colon cancer but not in the normal colonic mucosa. No association was observed with the clinical-pathologic parameters. However, patients expressing GalNAc-T6 had a significantly increased overall survival (median, 58 months; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|